Christa Elisabeth Müller

Christa Elisabeth Müller's AcademicInfluence.com Rankings

Medical

#2342

World Rank

#2761

Historical Rank

Pharmacology

#240

World Rank

#281

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Christa Elisabeth Müller Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Christa Elisabeth Müller's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update (2011) (1147)
Recent developments in adenosine receptor ligands and their potential as novel drugs. (2011) (373)
Structure of the human P2Y12 receptor in complex with an antithrombotic drug (2014) (337)
Adenosine activates brown adipose tissue and recruits beige adipocytes via A2A receptors (2014) (305)
Agonist-bound structure of the human P2Y12 receptor (2014) (287)
The experimental power of FR900359 to study Gq-regulated biological processes (2015) (251)
Striatal Adenosine A2A and Cannabinoid CB1 Receptors Form Functional Heteromeric Complexes that Mediate the Motor Effects of Cannabinoids (2007) (240)
Anthraquinones As Pharmacological Tools and Drugs (2016) (240)
CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. (2010) (236)
Caffeine acts through neuronal adenosine A2A receptors to prevent mood and memory dysfunction triggered by chronic stress (2015) (236)
Medicinal chemistry of adenosine, P2Y and P2X receptors (2016) (216)
CD39/Ectonucleoside Triphosphate Diphosphohydrolase 1 Provides Myocardial Protection During Cardiac Ischemia/Reperfusion Injury (2007) (204)
Involvement of Adenosine A1 and A2A Receptors in the Motor Effects of Caffeine after its Acute and Chronic Administration (2003) (187)
Dopaminergic Modulation of Effort-Related Choice Behavior as Assessed by a Progressive Ratio Chow Feeding Choice Task: Pharmacological Studies and the Role of Individual Differences (2012) (173)
Polyoxometalates--a new class of potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitors. (2006) (170)
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). (2011) (168)
Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis (2008) (165)
Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms (2008) (154)
Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. (2011) (149)
Adenosine Receptor Antagonists Including Caffeine Alter Fetal Brain Development in Mice (2013) (145)
Crystal structure of the human ecto-5'-nucleotidase (CD73): insights into the regulation of purinergic signaling. (2012) (140)
P2 receptors activated by uracil nucleotides--an update. (2006) (139)
Identification by Site-directed Mutagenesis of Residues Involved in Ligand Recognition and Activation of the Human A3 Adenosine Receptor* (2002) (138)
Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. (2001) (137)
Ecto-5′-Nucleotidase (CD73)-Mediated Formation of Adenosine Is Critical for the Striatal Adenosine A2A Receptor Functions (2013) (135)
Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease. (2004) (133)
Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A(1) adenosine receptors. (2002) (133)
Antinociceptive Effects of Novel A2B Adenosine Receptor Antagonists (2004) (133)
1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. (2009) (126)
Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A2A and dopamine D2 receptors (2002) (124)
Selective Activation of Adenosine A2A Receptors on Immune Cells by a CD73-Dependent Prodrug Suppresses Joint Inflammation in Experimental Rheumatoid Arthritis (2012) (123)
Polyoxometalates as Versatile Enzyme Inhibitors (2013) (123)
Adenosine A2A receptor blockade reverts hippocampal stress-induced deficits and restores corticosterone circadian oscillation (2013) (121)
P2Y₂ and Gq/G₁₁ control blood pressure by mediating endothelial mechanotransduction. (2015) (120)
Decoding Signaling and Function of the Orphan G Protein–Coupled Receptor GPR17 with a Small-Molecule Agonist (2013) (120)
Adenosine receptor agonists: from basic medicinal chemistry to clinical development (2003) (120)
1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists. (2002) (119)
Caffeine and an adenosine A2A receptor antagonist prevent memory impairment and synaptotoxicity in adult rats triggered by a convulsive episode in early life (2010) (119)
Xanthines as adenosine receptor antagonists. (2011) (117)
Effort-Related Motivational Effects of the VMAT-2 Inhibitor Tetrabenazine: Implications for Animal Models of the Motivational Symptoms of Depression (2013) (114)
Update of P2Y receptor pharmacology: IUPHAR Review 27 (2020) (114)
Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists. (2000) (114)
Age-related shift in LTD is dependent on neuronal adenosine A2A receptors interplay with mGluR5 and NMDA receptors (2018) (114)
A2A adenosine receptor deletion is protective in a mouse model of Tauopathy (2016) (112)
Adenosine receptors and their modulators. (1993) (111)
Adenosine A2A receptor blockade prevents memory dysfunction caused by β-amyloid peptides but not by scopolamine or MK-801 (2008) (110)
Contribution of E‐NTPDasel (CD39) to renal protection from ischemia‐reperfusion injury (2007) (109)
Update of P2X receptor properties and their pharmacology: IUPHAR Review 30 (2020) (109)
The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure (2009) (107)
Medicinal chemistry of adenosine A3 receptor ligands. (2003) (106)
Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors (2015) (101)
N-substituted phenoxazine and acridone derivatives: structure-activity relationships of potent P2X4 receptor antagonists. (2012) (99)
Adenosine A2A receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat: implications for studies of psychomotor slowing (2007) (97)
Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors. (2006) (96)
α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5'-Nucleotidase (CD73) Inhibitors. (2015) (95)
Ecto-ATPase inhibition: ATP and adenosine release under physiological and ischemic in vivo conditions in the rat striatum (2012) (93)
Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders. (2007) (92)
Polyoxometalates--potent and selective ecto-nucleotidase inhibitors. (2015) (91)
Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/ chow feeding choice task (2014) (86)
Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice (2016) (86)
The VMAT-2 Inhibitor Tetrabenazine Affects Effort-Related Decision Making in a Progressive Ratio/Chow Feeding Choice Task: Reversal with Antidepressant Drugs (2014) (86)
High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors. (2009) (84)
Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acid prodrugs with peroral bioavailability. (2004) (83)
l-DOPA-treatment in primates disrupts the expression of A2A adenosine–CB1 cannabinoid–D2 dopamine receptor heteromers in the caudate nucleus (2014) (83)
[3H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1h-imidazo[2,1-i]-purin-5- one ([3H]PSB-11), a novel high-affinity antagonist radioligand for human A3 adenosine receptors (2002) (82)
Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors. (1993) (81)
The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion (2015) (81)
Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs. (2006) (80)
The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists (2009) (80)
Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. (2010) (79)
Pharmacological evaluation of new constituents of “Spice”: synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds (2018) (79)
Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. (2001) (78)
Advances in immobilized enzyme microbioreactors in capillary electrophoresis. (2013) (75)
Dopamine/adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkinsonism. (2008) (74)
Interactions of valerian extracts and a fixed valerian-hop extract combination with adenosine receptors. (2002) (73)
Central P2Y12 receptor blockade alleviates inflammatory and neuropathic pain and cytokine production in rodents (2014) (73)
Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists. (1997) (72)
A capillary electrophoresis method for the characterization of ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) and the analysis of inhibitors by in-capillary enzymatic microreaction (2005) (71)
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling. (2009) (71)
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. (2002) (71)
Caffeine analogs: structure-activity relationships at adenosine receptors. (1991) (69)
Cardiac myocyte-secreted cAMP exerts paracrine action via adenosine receptor activation. (2014) (69)
Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists. (2002) (68)
Binding of [3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes--a new, selective antagonist radioligand for A(2A) adenosine receptors. (2000) (68)
Adenosine A2A receptor ligand recognition and signaling is blocked by A2B receptors (2018) (68)
Motor effects induced by a blockade of adenosine A2A receptors in the caudate‐putamen (1998) (67)
A detailed behavioral analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A1 and A2A receptors (2005) (67)
Indazole- and indole-5-carboxamides: selective and reversible monoamine oxidase B inhibitors with subnanomolar potency. (2014) (65)
Diindolylmethane Derivatives: Potent Agonists of the Immunostimulatory Orphan G Protein-Coupled Receptor GPR84. (2017) (64)
Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones. (2013) (64)
Elucidating the active δ-opioid receptor crystal structure with peptide and small-molecule agonists (2019) (63)
Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor. (2011) (63)
A1-Adenosine receptor antagonists (1997) (63)
Targeting the Main Protease of SARS‐CoV‐2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors (2021) (62)
Effects of an adenosine A2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in rats (2003) (61)
Rapid and efficient microwave-assisted copper(0)-catalyzed ullmann coupling reaction: general access to anilinoanthraquinone derivatives. (2007) (61)
Mass spectrometric identification of modified urinary nucleosides used as potential biomedical markers by LC–ITMS coupling (2005) (61)
Allosteric modulators of rhodopsin-like G protein-coupled receptors: opportunities in drug development. (2012) (61)
Structural Mapping of Adenosine Receptor Mutations: Ligand Binding and Signaling Mechanisms. (2018) (61)
Structure-activity relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases (E-NTPDases) (2008) (60)
Nucleoside-5'-monophosphates as prodrugs of adenosine A2A receptor agonists activated by ecto-5'-nucleotidase. (2009) (60)
The impact of adenosine and A2B receptors on glucose homoeostasis (2006) (60)
Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55. (2013) (58)
Effort-related motivational effects of the pro-inflammatory cytokine interleukin-6: pharmacological and neurochemical characterization (2016) (56)
Interaction of New, Very Potent Non-Nucleotide Antagonists with Arg256 of the Human Platelet P2Y12 Receptor (2009) (56)
GPR55: A therapeutic target for Parkinson's disease? (2017) (55)
Adenosine receptor ligands-recent developments part I. Agonists. (2000) (54)
Identification of a Potent and Selective Cannabinoid CB1 Receptor Antagonist from Auxarthron reticulatum. (2011) (54)
Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease (2018) (53)
Interaction of Purinergic P2X4 and P2X7 Receptor Subunits (2017) (53)
Recent developments in adenosine A2A receptor ligands. (2009) (53)
Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors. (2017) (53)
Stimulant effects of adenosine antagonists on operant behavior: differential actions of selective A2A and A1 antagonists (2011) (53)
Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats (2007) (53)
Treatment with A2A receptor antagonist KW6002 and caffeine intake regulate microglia reactivity and protect retina against transient ischemic damage (2017) (53)
Synthesis, characterization, and in vitro evaluation of the selective P2Y2 receptor antagonist AR-C118925 (2017) (53)
A2A adenosine receptor antagonists - future drugs for Parkinson's disease? (2000) (52)
Synthesis and structure-activity relationships of deazaxanthines: analogs of potent A1- and A2-adenosine receptor antagonists. (1994) (52)
Coordination of capsule assembly and cell wall biosynthesis in Staphylococcus aureus (2019) (52)
GPCR structure and activation: an essential role for the first extracellular loop in activating the adenosine A2B receptor (2011) (52)
Interactions between adenosine and dopamine receptor antagonists with different selectivity profiles: Effects on locomotor activity (2010) (51)
Imidazopyridine- and purine-thioacetamide derivatives: potent inhibitors of nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1). (2014) (51)
Enzymatic Properties of an Ecto-nucleoside Triphosphate Diphosphohydrolase from Legionella pneumophila (2008) (51)
Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold. (2013) (50)
BAY60-6583 Acts as a Partial Agonist at Adenosine A2B Receptors (2014) (50)
P2-pyrimidinergic receptors and their ligands. (2002) (49)
Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists. (2008) (49)
3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents. (2021) (49)
Synthesis of alkyl- and aryl-amino-substituted anthraquinone derivatives by microwave-assisted copper(0)-catalyzed Ullmann coupling reactions (2010) (48)
Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. (2009) (48)
Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats (2005) (47)
Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors. (2011) (47)
The caffeine-binding adenosine A2A receptor induces age-like HPA-axis dysfunction by targeting glucocorticoid receptor function (2016) (47)
2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors. (2003) (46)
Benzothiazinones: a novel class of adenosine receptor antagonists structurally unrelated to xanthine and adenine derivatives. (2012) (46)
Adenosine receptor subtype-selective antagonists in inflammation and hyperalgesia (2008) (46)
Synthesis and pharmacology of pyrido[2,3-d]pyrimidinediones bearing polar substituents as adenosine receptor antagonists. (2006) (46)
Interaction of valerian extracts of different polarity with adenosine receptors: identification of isovaltrate as an inverse agonist at A1 receptors. (2007) (45)
Extracellular NAD(+) induces a rise in [Ca(2+)](i) in activated human monocytes via engagement of P2Y(1) and P2Y(11) receptors. (2009) (45)
A new synthesis of sulfonamides by aminolysis of p-nitrophenylsulfonates yielding potent and selective adenosine A2B receptor antagonists. (2006) (45)
Molecular and functional interaction between GPR18 and cannabinoid CB2 G‐protein‐coupled receptors. Relevance in neurodegenerative diseases (2018) (45)
A1 adenosine receptors and their ligands: overview and recent developments. (2001) (44)
Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique adenosine derivative. (2004) (44)
Targeted inhibition of Gq signaling induces airway relaxation in mouse models of asthma (2017) (44)
The novel adenosine A2A antagonist prodrug MSX-4 is effective in animal models related to motivational and motor functions (2012) (44)
7-Deazaadenines bearing polar substituents: structure-activity relationships of new A(1) and A(3) adenosine receptor antagonists. (2000) (43)
Homology modelling of the human adenosine A2B receptor based on X-ray structures of bovine rhodopsin, the β2-adrenergic receptor and the human adenosine A2A receptor (2009) (42)
Heterologous Expression, Biosynthetic Studies, and Ecological Function of the Selective Gq-Signaling Inhibitor FR900359. (2018) (41)
P2Y12 Receptor Localizes in the Renal Collecting Duct and Its Blockade Augments Arginine Vasopressin Action and Alleviates Nephrogenic Diabetes Insipidus. (2015) (41)
Differential allosteric modulation by amiloride analogues of agonist and antagonist binding at A(1) and A(3) adenosine receptors. (2003) (41)
A2A adenosine receptor deletion is protective in a mouse model of Tauopathy (2016) (41)
Shear stress modulates endothelial KLF2 through activation of P2X4 (2015) (41)
Characterization of P2X4 receptor agonists and antagonists by calcium influx and radioligand binding studies (2017) (41)
Tools and drugs for uracil nucleotide‐activated P2Y receptors (2018) (41)
Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) Inhibitors. (2019) (40)
The second extracellular loop of GPCRs determines subtype-selectivity and controls efficacy as evidenced by loop exchange study at A2 adenosine receptors. (2013) (40)
A novel receptor cross-talk between the ATP receptor P2Y2 and formyl peptide receptors reactivates desensitized neutrophils to produce superoxide. (2014) (40)
Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family. (2009) (40)
Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5'-carboxamide. (2008) (39)
Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12‐receptor (2014) (39)
Alkynyl-coumarinyl ethers as MAO-B inhibitors. (2014) (39)
Virtual screening identifies novel sulfonamide inhibitors of ecto-5'-nucleotidase. (2012) (39)
Understanding the Role of Adenosine A2AR Heteroreceptor Complexes in Neurodegeneration and Neuroinflammation (2018) (39)
Ligand-specific binding and activation of the human adenosine A(2B) receptor. (2013) (39)
Oral tremor induced by the muscarinic agonist pilocarpine is suppressed by the adenosine A2A antagonists MSX-3 and SCH58261, but not the adenosine A1 antagonist DPCPX (2010) (38)
Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information (2015) (38)
8-(Sulfostyryl)xanthines: water-soluble A2A-selective adenosine receptor antagonists. (1998) (37)
Synthesis and Properties of a New Water-Soluble Prodrug of the Adenosine A2A Receptor Antagonist MSX-2 (2008) (37)
Capillary electrophoresis-based nanoscale assays for monitoring ecto-5'-nucleotidase activity and inhibition in preparations of recombinant enzyme and melanoma cell membranes. (2008) (36)
Indoloditerpenes from a marine-derived fungal strain of Dichotomomyces cejpii with antagonistic activity at GPR18 and cannabinoid receptors. (2014) (36)
Structural characterization and pharmacological evaluation of the new synthetic cannabinoid CUMYL-PEGACLONE. (2018) (35)
The four cysteine residues in the second extracellular loop of the human adenosine A2B receptor: role in ligand binding and receptor function. (2011) (35)
Identification of aurintricarboxylic acid as a potent allosteric antagonist of P2X1 and P2X3 receptors (2019) (35)
Development of Polar Adenosine A2A Receptor Agonists for Inflammatory Bowel Disease: Synergism with A2B Antagonists. (2011) (35)
Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors. (1993) (35)
P 2 Y 2 and G q / G 11 control blood pressure by mediating endothelial mechanotransduction (2019) (35)
7-Deaza-2-phenyladenines: structure-activity relationships of potent A1 selective adenosine receptor antagonists. (1990) (35)
Fast, efficient capillary electrophoresis method for measuring nucleotide degradation and metabolism. (2002) (35)
Carbamazepine derivatives with P2X4 receptor-blocking activity. (2014) (35)
Medicinal chemistry of P2X receptors: allosteric modulators. (2015) (34)
Oral tremor induced by galantamine in rats: A model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease (2011) (34)
Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease. (2014) (34)
Diabetes-induced Neuropathic Mechanical Hyperalgesia Depends on P2X4 Receptor Activation in Dorsal Root Ganglia (2019) (34)
Antiproliferative effects of selective adenosine receptor agonists and antagonists on human lymphocytes: evidence for receptor-independent mechanisms (2013) (34)
Chiral pyrrolo[2,3-d]pyrimidine and pyrimido[4,5-b]indole derivatives: structure-activity relationships of potent, highly stereoselective A1-adenosine receptor antagonists. (1996) (33)
8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35. (2013) (33)
6-Bromo-8-(4-[(3)H]methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic Acid: a powerful tool for studying orphan G protein-coupled receptor GPR35. (2013) (33)
Synthesis and preliminary evaluation of [3H]PSB-0413, a selective antagonist radioligand for platelet P2Y12 receptors. (2005) (33)
7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists. (2012) (33)
Imidazo-thiazine, -diazinone and -diazepinone derivatives. Synthesis, structure and benzodiazepine receptor binding. (2001) (33)
Role of P2 purinergic receptors in synaptic transmission under normoxic and ischaemic conditions in the CA1 region of rat hippocampal slices (2007) (33)
Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery. (2019) (32)
P2Y2 receptor agonist with enhanced stability protects the heart from ischemic damage in vitro and in vivo (2013) (32)
The platelet P2Y12 receptor under normal and pathological conditions. Assessment with the radiolabeled selective antagonist [3H]PSB-0413 (2013) (32)
Evidence for the Functional Expression and Pharmacological Characterization of Adenine Receptors in Native Cells and Tissues (2005) (32)
Synthesis of 3-substituted 6-aminouracils (1991) (31)
Characterization of human and rodent native and recombinant adenosine A2B receptors by radioligand binding studies (2006) (31)
2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. (2010) (31)
Cloning and Functional Expression of a Novel Gi Protein-Coupled Receptor for Adenine from Mouse Brain (2008) (31)
The Natural Product Magnolol as a Lead Structure for the Development of Potent Cannabinoid Receptor Agonists (2013) (31)
General Synthesis of Unsymmetrical 3,3'-(Aza)diindolylmethane Derivatives. (2018) (31)
CD 39 / Ectonucleoside Triphosphate Diphosphohydrolase 1 Provides Myocardial Protection During Cardiac Ischemia / Reperfusion Injury (2007) (31)
Development of Potent and Selective Antagonists for the UTP-Activated P2Y4 Receptor. (2017) (31)
Chemical Genetic Analysis and Functional Characterization of Staphylococcal Wall Teichoic Acid 2-Epimerases Reveals Unconventional Antibiotic Drug Targets (2016) (31)
Targeting renal purinergic signalling for the treatment of lithium‐induced nephrogenic diabetes insipidus (2015) (31)
Synthesis and biological activity of tricyclic aryloimidazo-, pyrimido-, and diazepinopurinediones. (2006) (30)
Effect of the adenosine A2A receptor antagonist MSX-3 on motivational disruptions of maternal behavior induced by dopamine antagonism in the early postpartum rat (2010) (30)
International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update (2022) (30)
Potent Suppressive Effects of 1-Piperidinylimidazole Based Novel P2X7 Receptor Antagonists on Cancer Cell Migration and Invasion. (2016) (30)
Impact of in vivo chronic blockade of adenosine A2A receptors on the BDNF-mediated facilitation of LTP (2014) (29)
Phenylethyl-substituted pyrimido[2,1-f]purinediones and related compounds: structure-activity relationships as adenosine A(1) and A(2A) receptor ligands. (2007) (29)
Characterization of new G protein-coupled adenine receptors in mouse and hamster (2013) (29)
Chronic and acute adenosine A2A receptor blockade prevents long-term episodic memory disruption caused by acute cannabinoid CB1 receptor activation (2017) (29)
Substrate-Dependence of Competitive Nucleotide Pyrophosphatase/Phosphodiesterase1 (NPP1) Inhibitors (2017) (28)
[(3)H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]-purin-5-one ([(3)H]PSB-11), a novel high-affinity antagonist radioligand for human A(3) adenosine receptors. (2002) (28)
2-Substituted α,β Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes. (2020) (27)
Impact of the aryl substituent kind and distance from pyrimido[2,1-f]purindiones on the adenosine receptor selectivity and antagonistic properties. (2003) (27)
Synthesis and biological activity of tricyclic cycloalkylimidazo-, pyrimido- and diazepinopurinediones. (2011) (27)
Conditional neural knockout of the adenosine A2A receptor and pharmacological A2A antagonism reduce pilocarpine-induced tremulous jaw movements: Studies with a mouse model of parkinsonian tremor (2013) (27)
Bispidines for dual imaging. (2014) (27)
Agonists and Antagonists for Purinergic Receptors. (2020) (27)
New developments in A1 and A2 adenosine receptor antagonists (2001) (27)
Synthesis of uracil nucleotide analogs with a modified, acyclic ribose moiety as P2Y(2) receptor antagonists. (2009) (26)
X‐Ray Co‐Crystal Structure Guides the Way to Subnanomolar Competitive Ecto‐5′‐Nucleotidase (CD73) Inhibitors for Cancer Immunotherapy (2019) (26)
Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice (2010) (26)
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y2 Receptor. (2017) (25)
High-sensitivity capillary electrophoresis method for monitoring purine nucleoside phosphorylase and adenosine deaminase reactions by a reversed electrode polarity switching mode. (2011) (25)
Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets. (2020) (24)
The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: Implications for pharmacological models of parkinsonian tremor (2013) (24)
N9-benzyl-substituted 1,3-dimethyl- and 1,3-dipropyl-pyrimido[2,1-f]purinediones: synthesis and structure-activity relationships at adenosine A1 and A2A receptors. (2007) (24)
Applying Molecular Networking for the Detection of Natural Sources and Analogues of the Selective Gq Protein Inhibitor FR900359. (2018) (24)
Ethanol and Caffeine Effects on Social Interaction and Recognition in Mice: Involvement of Adenosine A2A and A1 Receptors (2016) (24)
Characterization of non-olfactory GPCRs in human sperm with a focus on GPR18 (2016) (24)
A NEW VERSATILE SYNTHESIS OF XANTHINES WITH VARIABLE SUBSTITUENTS IN THE 1-, 3-, 7- AND 8-POSITIONS (1995) (24)
Extracellular Metabolism of Nucleotides in Neuroblastoma × Glioma NG108-15 Cells Determined by Capillary Electrophoresis (2003) (23)
Versatile, convenient synthesis of pyrimido[1,2,3-cd]purinediones (2003) (23)
Erratum: A2A adenosine receptor deletion is protective in a mouse model of Tauopathy (Molecular Psychiatry (2016) 21 149 (doi:10.1038/mp.2015.115)) (2016) (23)
Development and validation of a capillary electrophoresis method for the characterization of herpes simplex virus type 1 (HSV-1) thymidine kinase substrates and inhibitors. (2007) (23)
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases. (2013) (23)
Tricyclic oxazolo[2,3-f]purinediones: potency as adenosine receptor ligands and anticonvulsants. (2004) (22)
6-(Ar)Alkylamino-Substituted Uracil Derivatives: Lipid Mimetics with Potent Activity at the Orphan G Protein-Coupled Receptor 84 (GPR84) (2018) (22)
Crystal structure of NTPDase2 in complex with the sulfoanthraquinone inhibitor PSB-071. (2014) (22)
Cyclopropane-Containing Fatty Acids from the Marine Bacterium Labrenzia sp. 011 with Antimicrobial and GPR84 Activity (2018) (22)
Fluorescent-Labeled Selective Adenosine A2B Receptor Antagonist Enables Competition Binding Assay by Flow Cytometry. (2018) (21)
Stimulation of calcium release by caffeine analogs in pheochromocytoma cells. (1993) (21)
Role of extracellular cysteine residues in the adenosine A2A receptor (2016) (21)
Catalyst-free microwave-assisted amination of 2-chloro-5-nitrobenzoic acid. (2007) (21)
A novel P2X2‐dependent purinergic mechanism of enteric gliosis in intestinal inflammation (2020) (21)
A2A‐selective adenosine receptor antagonists: Development of water‐soluble prodrugs and a new tritiated radioligand (1998) (21)
P2Y2 receptor modulates shear stress-induced cell alignment and actin stress fibers in human umbilical vein endothelial cells (2016) (21)
Structural analogues of the natural products magnolol and honokiol as potent allosteric potentiators of GABA(A) receptors. (2014) (21)
Emerging structures and ligands for P2X3 and P2X4 receptors—towards novel treatments of neuropathic pain (2010) (21)
P2Y2 Receptor Promotes High-Fat Diet-Induced Obesity (2020) (20)
Adenosine A2A agonist and A2B antagonist mediate an inhibition of inflammation-induced contractile disturbance of a rat gastrointestinal preparation (2010) (20)
A2A and A2B adenosine receptors: the extracellular loop 2 determines high (A2A) or low affinity (A2B) for adenosine. (2019) (20)
8‐Benzyltetrahydropyrazino[2,1‐f]purinediones: Water‐Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases (2014) (20)
Analysis of the Staphylococcus aureus capsule biosynthesis pathway in vitro: characterization of the UDP-GlcNAc C6 dehydratases CapD and CapE and identification of enzyme inhibitors. (2014) (20)
Synthesis of BODIPY Derivatives Substituted with Various Bioconjugatable Linker Groups: A Construction Kit for Fluorescent Labeling of Receptor Ligands (2013) (20)
General synthesis and properties of 1-monosubstituted xanthines (1993) (19)
Nanodiscs for INPHARMA NMR Characterization of GPCRs: Ligand Binding to the Human A2A Adenosine Receptor. (2017) (19)
Configurationally stable analogs of styrylxanthines as A2A adenosine receptor antagonist (1997) (19)
A Group of Cationic Amphiphilic Drugs Activates MRGPRX2 and Induces Scratching Behavior in Mice. (2021) (19)
A new synthesis of thiophosphoric acid esters with a C-S-P bond (1990) (19)
5-Substituted UTP derivatives as P2Y2 receptor agonists (1999) (19)
Methylxanthines block antigen-induced responses in RBL-2H3 cells independently of adenosine receptors or cyclic AMP: evidence for inhibition of antigen binding to IgE. (1991) (19)
Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism: interaction with the effects of adenosine A2A antagonism (2013) (19)
Convergent Synthesis of the Potent P2Y Receptor Antagonist MG 50-3-1 Based on a Regioselective Ullmann Coupling Reaction (2012) (18)
2‐Amino[1,2,4]triazolo[1,5‐c]quinazolines and Derived Novel Heterocycles: Syntheses and Structure–Activity Relationships of Potent Adenosine Receptor Antagonists (2016) (18)
PSB 603 - a known selective adenosine A2B receptor antagonist - has anti-inflammatory activity in mice. (2020) (18)
Bicyclic imidazole-4-one derivatives: a new class of antagonists for the orphan G protein-coupled receptors GPR18 and GPR55 (2014) (18)
Cell‐permeable high‐affinity tracers for Gq proteins provide structural insights, reveal distinct binding kinetics and identify small molecule inhibitors (2019) (17)
Soluble and membrane-bound adenylate kinase and nucleotidases augment ATP-mediated inflammation in diabetic retinopathy eyes with vitreous hemorrhage (2019) (17)
3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17. (2018) (17)
Synthesis and preliminary evaluation of new 1- and 3-[1-(2-hydroxy-3-phenoxypropyl)]xanthines from 2-amino-2-oxazolines as potential A1 and A2A adenosine receptor antagonists. (2006) (17)
Thiazolo[3,2-a]benzimidazol-3(2H)-one derivatives: Structure-activity relationships of selective nucleotide pyrophosphatase/phosphodiesterase1 (NPP1) inhibitors. (2016) (17)
8-Substituted 1,3-dimethyltetrahydropyrazino[2,1-f]purinediones: Water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitors. (2016) (17)
Memory deficits induced by chronic cannabinoid exposure are prevented by adenosine A2AR receptor antagonism (2019) (17)
Adenosine A2A receptor agonists with potent antiplatelet activity (2018) (17)
Medicinal chemistry of a2B adenosine receptors (2018) (17)
Syntheses of 2-substituted 1-amino-4-bromoanthraquinones (bromaminic acid analogues) – precursors for dyes and drugs (2015) (16)
Imidazo[2,1-b]thiazoles, imidazo[2,1-b]imidazoles and Pyrrolo[1,2-c]imidazoles. synthesis, structure and evaluation of benzodiazepine receptor binding (2002) (16)
Imidazo[2,1-b]thiazepines: synthesis, structure and evaluation of benzodiazepine receptor binding. (2004) (16)
Radiosynthesis and in vivo evaluation of a fluorine-18 labeled pyrazine based radioligand for PET imaging of the adenosine A2B receptor. (2018) (16)
Decarboxylative Coupling Reaction of 2‐(1 H ‐Indol‐3‐yl)acetic Acids with Indole, Azaindole, Benzimidazole and Indazole Derivatives (2019) (16)
Extracellular adenosine reversibly inhibits the activation of human regulatory T cells and negatively influences the achievement of the operational tolerance in liver transplantation (2018) (16)
A highly sensitive capillary electrophoresis method using p-nitrophenyl 5'-thymidine monophosphate as a substrate for the monitoring of nucleotide pyrophosphatase/phosphodiesterase activities. (2012) (16)
An agonist radioligand for the proinflammatory lipid-activated G protein-coupled receptor GPR84 providing structural insights. (2019) (16)
Clopidogrel attenuates lithium-induced alterations in renal water and sodium channels/transporters in mice (2015) (15)
Expression of Ecto-nucleoside Triphosphate Diphosphohydrolases-2 and -3 in the Enteric Nervous System Affects Inflammation in Experimental Colitis and Crohn’s Disease (2017) (15)
Thermal proteome profiling identifies the membrane-bound purinergic receptor P2X4 as a target of the autophagy inhibitor indophagolin. (2021) (15)
Efficient and mild deamination procedure for 1-aminoanthraquinones yielding a diverse library of novel derivatives with potential biological activity (2012) (15)
GPR18 Inhibiting Amauromine and the Novel Triterpene Glycoside Auxarthonoside from the Sponge-Derived Fungus Auxarthron reticulatum (2015) (15)
Synthesis and structure-activity relationships of quinolinone and quinoline-based P2X7 receptor antagonists and their anti-sphere formation activities in glioblastoma cells. (2018) (15)
Lack of adenosine A1 and dopamine D2 receptor-mediated modulation of the cardiovascular effects of the adenosine A2A receptor agonist CGS 21680. (2004) (15)
Evaluation of anticonvulsant and analgesic effects of benzyl- and benzhydryl ureides. (2007) (15)
The rat adenine receptor: pharmacological characterization and mutagenesis studies to investigate its putative ligand binding site (2013) (15)
Ullmann reactions of 1-amino-4-bromoanthraquinones bearing various 2-substituents furnishing novel dyes (2016) (15)
Tritium-labeled agonists as tools for studying adenosine A2B receptors (2018) (14)
Similarities and differences in affinity and binding modes of tricyclic pyrimido- and pyrazinoxanthines at human and rat adenosine receptors. (2016) (14)
Aza‐Analogs of 8‐Styrylxanthines as A2A‐Adenosine Receptor Antagonists (1997) (14)
Chromenones as Multineurotargeting Inhibitors of Human Enzymes (2019) (14)
Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors (2020) (14)
Fluorescence polarization immunoassays for monitoring nucleoside triphosphate diphosphohydrolase (NTPDase) activity. (2015) (14)
2-phenyl-1-[4-(2-piperidine-1-yl-ethoxy)benzyl]-1H-benzimidazoles as ligands for the estrogen receptor: synthesis and pharmacological evaluation. (2010) (13)
Dissection of P2X4 and P2X7 Receptor Current Components in BV-2 Microglia (2020) (13)
The map kinase ERK regulates renal activity of cyclin-dependent kinase 2 in experimental glomerulonephritis. (2007) (13)
Development of spin-labeled probes for adenosine receptors. (2005) (13)
Development of [(3)H]2-Carboxy-4,6-dichloro-1H-indole-3-propionic Acid ([(3)H]PSB-12150): A Useful Tool for Studying GPR17. (2014) (13)
Preyssler-Pope-Jeannin Polyanions [NaP5 W30 O110 ]14- and [AgP5 W30 O110 ]14- : Microwave-Assisted Synthesis, Structure, and Biological Activity (2018) (13)
Microwave-assisted ring closure reactions: Synthesis of 8-substituted xanthine derivatives and related pyrimido- and diazepinopurinediones (2006) (13)
Hippocampal synaptic dysfunction in the SOD1G93A mouse model of Amyotrophic Lateral Sclerosis: Reversal by adenosine A2AR blockade (2020) (13)
Domains for activation and inactivation in G protein-coupled receptors--a mutational analysis of constitutive activity of the adenosine A2B receptor. (2014) (13)
Novel multi-target directed ligands based on annelated xanthine scaffold with aromatic substituents acting on adenosine receptor and monoamine oxidase B. Synthesis, in vitro and in silico studies. (2019) (12)
Chemistry of porphyrins in fossil plants and animals (2021) (12)
Regioselective synthesis of 7,8-dihydroimidazo[5,1-c][1,2,4]triazine-3,6(2H,4H)-dione derivatives: A new drug-like heterocyclic scaffold (2012) (12)
Rapid microwave-assisted fluorination yielding novel 5'-deoxy-5'-fluorouridine derivatives. (2006) (12)
1‐Substituted 4‐[Chloropyrazolyl][1,2,4]triazolo[4,3‐a]quinoxalines: Synthesis and Structure‐Activity Relationships of a New Class of Benzodiazepine and Adenosine Receptor Ligands (1998) (12)
Focused screening to identify new adenosine kinase inhibitors. (2016) (12)
Caffeine modulates voluntary alcohol intake in mice depending on the access conditions: Involvement of adenosine receptors and the role of individual differences (2019) (12)
Ammonium-induced calcium mobilization in 1321N1 astrocytoma cells. (2008) (12)
A2B Adenosine Receptor Antagonists with Picomolar Potency. (2019) (12)
Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast®) in rat small intestinal preparations (2012) (12)
Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18. (2018) (12)
Recombinant expression of ecto-nucleotide pyrophosphatase/phosphodiesterase 4 (NPP4) and development of a luminescence-based assay to identify inhibitors. (2020) (11)
Fast, Efficient, and Versatile Synthesis of 6-amino-5-carboxamidouracils as Precursors for 8-Substituted Xanthines (2019) (11)
Synthesis, biological activity and molecular modelling studies of tricyclic alkylimidazo-, pyrimido- and diazepinopurinediones (2013) (11)
P2Y1‐like nucleotide receptors—Structures, molecular modeling, mutagenesis, and oligomerization (2020) (11)
Sphingosine-1-phosphate induces migration of microglial cells via activation of volume-sensitive anion channels, ATP secretion and activation of purinergic receptors. (2020) (11)
Synthesis of 8-Substituted Xanthine Derivatives by Suzuki Cross-Coupling Reaction (2002) (11)
An experimental strategy to probe Gq contribution to signal transduction in living cells (2021) (11)
Development of a microbioreactor with ecto-nucleoside triphosphate diphosphohydrolase 2 (NTPDase2) immobilized on a polyacrylamide-coated capillary at the outlet. (2010) (11)
Angiotensin II type 1/adenosine A2A receptor oligomers: a novel target for tardive dyskinesia (2017) (11)
Thioesterase-mediated side chain transesterification generates potent Gq signaling inhibitor FR900359 (2021) (11)
Prasugrel suppresses development of lithium-induced nephrogenic diabetes insipidus in mice (2016) (11)
Computational Investigations on the Binding Mode of Ligands for the Cannabinoid-Activated G Protein-Coupled Receptor GPR18 (2020) (11)
Nucleotide P2Y1 receptor agonists are in vitro and in vivo prodrugs of A1/A3 adenosine receptor agonists: implications for roles of P2Y1 and A1/A3 receptors in physiology and pathology (2020) (11)
Cellular localization of adenine receptors in the rat kidney and their functional significance in the inner medullary collecting duct. (2013) (10)
Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y12 receptor-mediated platelet aggregation (2012) (10)
SYNTHESIS OF PARAXANTHINE AND ISOPARAXANTHINE ANALOGS (1,7- AND 1,9-SUBSTITUTED XANTHINE DERIVATIVES) (1998) (10)
Discovery of Tricyclic Xanthines as Agonists of the Cannabinoid-Activated Orphan G-Protein-Coupled Receptor GPR18. (2020) (10)
Synthesis of Novel Potent Archazolids: Pharmacology of an Emerging Class of Anticancer Drugs. (2020) (10)
Design, synthesis and biological evaluation of suramin-derived dual antagonists of the proinflammatory G protein-coupled receptors P2Y2 and GPR17. (2019) (10)
A Novel Ring Closure Reaction for the Preparation of 6-Aminouracils with an a-Branched 1-Substituent (2000) (10)
Arylidene imidazothiazoles. Synthesis, structure and benzodiazepine receptor binding (1999) (9)
Tritium‐Labeled Brivaracetam with High Specific Activity: Preparation, Characterization and Application in Human Brain Samples (2012) (9)
Uridine Nucleotide Receptors and Their Ligands: Structural, Physiological, and Pathophysiological Aspects, with Special Emphasis on the Nervous System (1997) (9)
Investigation on 2',3'-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists. (2018) (9)
Fluorescent Probes for Ecto-5'-nucleotidase (CD73). (2020) (9)
Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/ chow feeding choice task (2013) (9)
Inhibitors for the bacterial ectonucleotidase Lp1NTPDase from Legionella pneumophila. (2016) (9)
Interaction of Approved Drugs with Synaptic Vesicle Protein 2A (2017) (9)
Development of Anthraquinone Derivatives as Ectonucleoside Triphosphate Diphosphohydrolase (NTPDase) Inhibitors With Selectivity for NTPDase2 and NTPDase3 (2020) (9)
Macrocyclic Gq Protein Inhibitors FR900359 and/or YM-254890-Fit for Translation? (2021) (8)
Tricyclic xanthine derivatives containing a basic substituent: adenosine receptor affinity and drug-related properties. (2018) (8)
Adenosine A2A Receptor Antagonists in Drug Development (2015) (8)
New developments in A 1 and A 2 adenosine receptor antagonists (2001) (8)
Improved synthesis of 4-/6-substituted 2-carboxy-1H-indole-3-propionic acid derivatives and structure–activity relationships as GPR17 agonists (2014) (8)
Synthesis of Novel Pyrido[3,2‐e][1,2,4]triazolo[1,5‐c]pyrimidine Derivatives: Potent and Selective Adenosine A3 Receptor Antagonists (2013) (8)
Mechanism underlying the contractile activity of UTP in the mammalian heart (2018) (8)
Genome Editing in Neuroepithelial Stem Cells to Generate Human Neurons with High Adenosine‐Releasing Capacity (2018) (7)
G-Protein-Coupled Receptors: Sustained Signaling via Intracellular Megaplexes and Pathway-Specific Drugs. (2016) (7)
Substituted 4-phenylthiazoles: Development of potent and selective A1, A3 and dual A1/A3 adenosine receptor antagonists. (2019) (7)
Facile synthesis of 5-amino- and 7-amino-6-azaoxindole derivatives (2012) (7)
GPR 55 : A therapeutic target for Parkinson ' s disease ? (2017) (7)
Development of Chromen-4-one Derivatives as (Ant)agonists for the Lipid-Activated G Protein-Coupled Receptor GPR55 with Tunable Efficacy (2019) (7)
A(3) adenosine receptor antagonists. (2001) (7)
Novel, Dual Target‐Directed Annelated Xanthine Derivatives Acting on Adenosine Receptors and Monoamine Oxidase B (2020) (7)
Discovery and structure-relationships of salicylanilide derivatives as potent, non-acidic P2X1 receptor antagonists. (2020) (7)
P2Y receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (7)
Induction of oral tremor in mice by the acetylcholinesterase inhibitor galantamine: Reversal with adenosine A2A antagonism (2016) (6)
Development of a selective and highly sensitive fluorescence assay for nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39). (2018) (6)
Effects of GPR18 Ligands on Body Weight and Metabolic Parameters in a Female Rat Model of Excessive Eating (2021) (6)
[3H]Adenine is a suitable radioligand for the labeling of G protein-coupled adenine receptors but shows high affinity to bacterial contaminations in buffer solutions (2007) (6)
Lipophilic disulfide prodrugs — syntheses and disulfide bond cleavage (1989) (6)
Tricyclic theophylline derivatives with high water-solubility: structure-activity relationships at adenosine receptors, phosphodiesterases, and benzodiazepine binding sites. (1995) (6)
Ligand binding and activation of UTP-activated G protein-coupled P2Y2 and P2Y4 receptors elucidated by mutagenesis, pharmacological and computational studies. (2019) (6)
BAY 60-6583 acts as a partial agonist at adenosine A 2 B receptors (2014) (6)
Discovery of potent nucleotide pyrophosphatase/phosphodiesterase3 (NPP3) inhibitors with ancillary carbonic anhydrase inhibition for cancer (immuno)therapy. (2021) (5)
Improved, Efficient Synthesis for Multigram-Scale Production of PSB-10, a Potent Antagonist at Human A3 Adenosine Receptors (2003) (5)
Structure-activity relationships of agonists for the orphan G protein-coupled receptor GPR27. (2021) (5)
Modulating P1 Adenosine Receptors in Disease Progression of SOD1G93A Mutant Mice (2019) (5)
A SIMPLE METHOD TO PREPARE HOMOALLYLIC AMINES FROM SECONDARY HOMOALLYLIC MESYLATES (1995) (4)
Synthesis of a hydrolytically stable, fluorescent-labeled ATP analog as a tool for probing adenylyl cyclases. (2010) (4)
Correction to: Identification of adenine-N9-(methoxy)ethyl-β-bisphosphonate as NPP1 inhibitor attenuates NPPase activity in human osteoarthritic chondrocytes (2019) (4)
8-Benzylaminoxanthine scaffold variations for selective ligands acting on adenosine A2A receptors. Design, synthesis and biological evaluation. (2020) (4)
Structural and Conformational Studies on Carboxamides of 5,6-Diaminouracils—Precursors of Biologically Active Xanthine Derivatives (2019) (4)
Identification of adenine-N9-(methoxy)ethyl-β-bisphosphonate as NPP1 inhibitor attenuates NPPase activity in human osteoarthritic chondrocytes (2019) (4)
Development of high-affinity fluorinated ligands for cannabinoid subtype 2 receptor, and in vitro evaluation of a radioactive tracer for imaging. (2022) (4)
A capillary electrophoresis method with dynamic pH junction stacking for the monitoring of cerebroside sulfotransferase. (2015) (4)
Crystal structure of 1-propyl-8-(4-sulfophenyl)-7H-imidazo[4,5-d]pyrimidin- 2,6(1H,3H)-dione dihydrate, C14H14N4O5S 2H2O (1997) (4)
Synthesis of xanthine derivatives by microwave-assisted ring closure reaction (2005) (4)
Preparation of enantiopure (R)-hydroxy metabolite of denbufylline using immobilized Lactobacillus kefiri DSM 20587 as a catalyst. (2009) (4)
Synthesis of tritium-labeled levetiracetam ((2S)-2-(2-oxopyrrolidin-1-yl)butanamide) with high specific activity (2012) (4)
Sulfated Polysaccharides from Macroalgae Are Potent Dual Inhibitors of Human ATP-Hydrolyzing Ectonucleotidases NPP1 and CD39 (2021) (4)
A Cellular Assay for the Identification and Characterization of Connexin Gap Junction Modulators (2021) (4)
[3H]BQ-123 Binding to Native Endothelin ETA Receptors in Human Astrocytoma 1321N1 Cells and Screening of Potential Ligands (2005) (4)
Inhibition of phytohemagglutinine-induced T lymphocyte proliferation by 6-(octadecyldithio)purine, a novel liposomal prodrug of 6-mercaptopurine. (1989) (4)
Quantification of green fluorescent protein-(GFP-) tagged membrane proteins by capillary gel electrophoresis. (2017) (4)
GPR18-Mediated Relaxation of Human Isolated Pulmonary Arteries (2022) (3)
Erratum to: Characterization of circulating microparticle-associated CD39 family ecto-nucleotidases in human plasma (2014) (3)
Phenylpropanolamine - a review. Von L. Lasagna; J. Wiley & Sons, Inc., New York/Chichester/Brisbane/Toronto/Singapore, 1988, 440 S., 40 Abb., 63 Tab., £ 34,50 (1989) (3)
Crystal structure of 4-bromobutyric acid 3-((4,4-difluoro-1,3,5,7-tetramethyl- 4-bora-3a,4a-diaza-s-indacen)-8-yl)propyl ester, C20H26BBrF2N2O2 (2002) (3)
Adenine-(methoxy)-ethoxy-Pα,α-dithio-triphosphate inhibits pathologic calcium pyrophosphate deposition in osteoarthritic human chondrocytes. (2019) (3)
Basic Chemistry of 2-Nitroimidazoles (Azomycin Derivatives) (1999) (3)
Adenosine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (3)
Development of a Radiofluorinated Adenosine A2B Receptor Antagonist as Potential Ligand for PET Imaging (2020) (3)
Synthesis and Analgesic Activity of Annelated Xanthine Derivatives in Experimental Models in Rodents (2015) (3)
Probing Substituents in the 1- and 3-Position: Tetrahydropyrazino-Annelated Water-Soluble Xanthine Derivatives as Multi-Target Drugs With Potent Adenosine Receptor Antagonistic Activity (2018) (3)
Synthesis and structure-activity relationships of cerebroside analogues as substrates of cerebroside sulphotransferase and discovery of a competitive inhibitor (2020) (3)
Adenosine A2AR/A1R Antagonists Enabling Additional H3R Antagonism for the Treatment of Parkinson's Disease. (2021) (3)
Feature-Based Molecular Networking for the Targeted Identification of Gq-Inhibiting FR900359 Derivatives. (2021) (3)
Crystal structure of 3-benzyl-5,5-dimethylimidazolidine-2,4-dione, C12H14N2O2 (2009) (2)
[Progress in cannabis research from a pharmaceutical chemist's point of view]. (2019) (2)
Adenosine Receptors: Therapeutic Aspects for Inflammatory and Immune Diseases. Edited by Gyorgy Hasko, Bruce N. Cronstein and Csaba Szabo. (2008) (2)
Development of a 5-hydroxytryptamine(2A) receptor binding assay for high throughput screening using 96-well microfilter plates. (2000) (2)
International Conference on Purinergic Drugs and Targets—4th Joint German–Italian Purine Club Meeting, Bonn, Germany, July 22–25, 2011 (2012) (2)
Crystal structure of 8-(5-bromopentyl)-4,4-difluoro-1,3,5,7-tetramethyl- 4-bora-3a,4a-diaza-s-indacene, C18H24BBrF2N2 (2002) (2)
Frontiers in CNS Drug Discovery (2017) (2)
Back Cover: 2-Amino[1,2,4]triazolo[1,5-c]quinazolines and Derived Novel Heterocycles: Syntheses and Structure–Activity Relationships of Potent Adenosine Receptor Antagonists (ChemMedChem 20/2016) (2016) (2)
CD73 controls ocular adenosine levels and protects retina from light-induced phototoxicity (2021) (2)
Caffeine exposure during pregnancy disrupts GABAergic circuits in offspring (2012) (2)
Adenosine receptors in GtoPdb v.2021.2 (2021) (2)
Koala and Wombat Gammaherpesviruses Encode the First Known Viral NTPDase Homologs and Are Phylogenetically Divergent from All Known Gammaherpesviruses (2018) (2)
Sensitive LC-MS/MS Method for the Quantification of Macrocyclic Gαq Protein Inhibitors in Biological Samples (2020) (2)
Unraveling binding mechanism and kinetics of macrocyclic Gαq protein inhibitors. (2021) (2)
Cellular Localization of P0 (Adenine) Receptor in Rat Kidney (2012) (2)
5,5'-BIPYRIDYL-2,4,6,2',4',6'-HEXAONE DERIVATIVES (HYDURILIC ACIDS) : SYNTHESES, MECHANISM OF C-C-BOND FORMATION AND PROPERTIES OF THE DIMERIC BARBITURIC ACID DERIVATIVES (2009) (2)
Formation of 7,9-Disubstituted Xanthinium Compounds Under Mild Conditions by Alkylation of Silylated Xanthines (1994) (1)
Crystal structure of 8-(5-bromopentyl)-4,4-difluoro-1,3,5,7-tetramethyl- 4-bora-3a,4a-diaza-s-indacene, C18H24BBrF2N2 (2002) (1)
The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion (2014) (1)
Ethanol and Caffeine Effects on Social Interaction and Recognition in Mice : Involvement of Adenosine A 2 A and A 1 Receptors Journal Item (2019) (1)
pain and cytokine production in rodents (2014) (1)
Effort-related motivational effects of the pro-inflammatory cytokine interleukin-6: pharmacological and neurochemical characterization (2016) (1)
P2Y receptors in GtoPdb v.2021.3 (2021) (1)
Synthesis of Novel Fluorinated Xanthine Derivatives with High Adenosine A2B Receptor Binding Affinity (2021) (1)
Amino-substituted 1,8-naphthyridines and pyrido[2,3-d]pyrimidines: new compounds with affinity for A1- and A2-adenosine receptors. (1994) (1)
The platelet P2Y12 receptor under normal and pathological conditions. Assessment with the radiolabeled selective antagonist [3H]PSB-0413 (2012) (1)
PURINES 2014: Nucleotides, nucleosides and nucleobases - international conference on signalling, drugs and targets (2014) (1)
Irreversible Antagonists for the Adenosine A2B Receptor (2022) (1)
New fluorescent-labeled adenosine receptor ligands (2010) (0)
Modulating P1 Adenosine Receptors in Disease Progression of SOD1G93A Mutant Mice (2019) (0)
Crystal structure of 4-bromobutyric acid 3-((4,4-difluoro-1,3,5,7-tetramethyl- 4-bora-3a,4a-diaza-s-indacen)-8-yl)propyl ester, C20H26BBrF2N2O2 (2002) (0)
Preliminary Evidence of the Potent and Selective Adenosine A2B Receptor Antagonist PSB-603 in Reducing Obesity and Some of Its Associated Metabolic Disorders in Mice (2022) (0)
Development of pharmacological modulators for the orphan G protein-coupled receptor GPR 17 and their application for the investigation of molecular signal transduction pathways (2011) (0)
Crystal structure of 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-hydroxymethyltetrahydrofuran- 2-yl)-2-propylsulfanyl-1H-pyrimidin-4-one, C12H18N2O5S (2009) (0)
Soluble and membrane-bound adenylate kinase and nucleotidases augment ATP-mediated inflammation in diabetic retinopathy eyes with vitreous hemorrhage (2019) (0)
Effect of adenosine A2A adenosine receptor antagonists on the activity of nigrostriatal DA neurons and catalepsy in rats (2010) (0)
Characterization of new G protein-coupled adenine receptors in mouse and hamster (2013) (0)
P76 synthesis and adenosine receptor affinity of S-substituted 2-thioxanthine analogues (1994) (0)
Helmholtz-Zentrum Dresden-Rossendorf (HZDR) Expression of ecto-nucleoside triphosphate diphosphohydrolases-2 and -3 by the enteric nervous system impacts inflammation in experimental colitis and Crohn’s disease (2020) (0)
Crystal structure of 6-amino-3-cyclopropyl-1-ethyl-1Hpyrimidine- 2,4-dione hydrate, C9H13N3O2 · H2O (2010) (0)
Cloning and expression of deoxyhypusine synthase from Plasmodium vivax and Theileria parva as an approach for target evaluation in antiparasitic chemotherapy (2009) (0)
P75 structure-activity relationships of DMPX (3,7-dimethyl-1-propargylxanthine) derivatives and analogs-potent A2-selective adenosine receptor antagonists (1994) (0)
Tools and Drugs for Purine-Binding Targets—Important Players in Inflammation and Cancer (2019) (0)
Crystal structure of 6-amino-3-methyI-5-nitrosopyrimidine-2,4(1H,3H)- dione monosodium dihydrate, C5H5N4O3Na · 2H2O (1998) (0)
Protective Effects of Ecto-nucleoside Triphosphate Diphosphohydrolases 2 and 3 (NTPDase 2 and 3) in Mouse Models of Colitis and Associations in Crohnʼs Disease: 638 (2016) (0)
P2X4 receptors mediate atheroprotective gene expression in an in vitro model of steady flow in vascular endothelial cells (696.6) (2014) (0)
[Synthesis of computer graphic calculated high-anti-fixed pyrimidine nucleoside analogs with potential virostatic and antineoplastic action]. (1989) (0)
The 2016 Frontiers in Medicinal Chemistry Conference in Bonn (2017) (0)
Crystal structure of 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-hydroxymethyl-tetrahydrofuran-2-yl)-2-propylsulfanyl-1H-pyrimidin-4-one, C12H18N2O5S (2009) (0)
Mode and site of interaction of the novel antiplatelet drug ticagrelor at the recombinant human P2Y12 receptor (1057.11) (2014) (0)
Pharmacological characterization of novel ligands of P2X3 receptor (2017) (0)
3.126 EVALUATION OF DRUGS ACTING ON CB1-A2A RECEPTOR OLIGOMERS IN RAT MODELS OF PARKINSON'S DISEASE (2012) (0)
Crystal structure of P2Y12 receptor in complex with 2MeSADP (2014) (0)
Abstract 17620: Paracrine Actions of the Intracellular Second Messenger cAMP Secreted From Cardiac Myocytes (2013) (0)
Crystal structure of 3-benzyl-5,5-dimethyiimidazolidine-2,4-dione, C12H14N2O2 (2009) (0)
A Combined Experimental and Simulation Approach to Develop Selective High-Affinity Small-Molecule Inhibitors of Cannabinoid Receptors CB1/CB2 (2011) (0)
Development of capillary electrophoresis protocols for the selection of aptamers targeting CD73 (2016) (0)
Characterisation of anti-inflammatory effects of STW5 and STW6 on rat small intestine in vitro: Involvement of adenosine A2A receptors (2007) (0)
Crystal structure of the active delta opioid receptor in complex with the small molecule agonist DPI-287 (2019) (0)
Data Citation: Giving Credit where Credit is Due (2018) (0)
Emerging Drugs and Targets for Parkinson’s Disease. Edited by Ana Martinez and Carmen Gil (2014) (0)
SC20 a new versatile strategy for the synthesis of xanthines with high adenosine receptor affinity and subtype-selectivity (1994) (0)
P5.005 Influence of adenosine A2A receptor agonist (CGS 21680) and antagonist (MSX-3) on the locomotor and sensitizing effects of cocaine (2004) (0)
Helmholtz-Zentrum Dresden-Rossendorf (HZDR) Preyssler-Pope-Jeannin Polyanions [NaP5W30O110]14- and [AgP5W30O110]14-: Synthesis, Structural Characterization, Electrochemistry, Antiproliferative and Antibacterial Activity (2020) (0)
Crystal structure of 9-benzyl-6-ethoxy-7-ethyl-2-phenyl-7,9- dihydropurin-8-one, C22H22N4O2 (2003) (0)
A Simple Method to Prepare Homoallylic Amines from Secondary Homoallylic Mesylates. (1995) (0)
Adenosine receptors in nociception, inflammation and hyperalgesia: a role for the A2B adenosine receptor (2003) (0)
Adenosine Receptors: New Targets to Protect Against Tissue Damage in Inflammatory Bowel Symptoms (2012) (0)
Neuroprotective effects of adenosine A2A antagonists in rats chronically infused with MPP+ into the cerebral ventricle through Alzet osmotic minipumps (2010) (0)
The Reactivity of Related 6-Amino- and 5,6-Diaminouracils Derived from 2-Amino-5-(phenoxymethyl)-2-oxazoline: Efficient Access to Bicyclic Pyrimidine Derivatives (2007) (0)
[The medicinal chemistry of diuretics]. (2006) (0)
CCDC 262107: Experimental Crystal Structure Determination (2006) (0)
Microglial purinergic receptors in Alzheimer's disease (2014) (0)
Crystal structure of the active delta opioid receptor in complex with the peptide agonist KGCHM07 (2019) (0)
[Adenosine receptor ligands--drugs of the future?]. (1989) (0)
Structure activity relationship of 3‐methylcytidine‐5’‐α,β‐methylenediphosphates as CD73 inhibitors (2022) (0)
Improving the Therapeutic Index of Mithramycin for the Treatment of Ewing Sarcoma (2014) (0)
Adenosine receptors in inflammation on rat colon preparations (2015) (0)
Su1318 – P2X2 Receptor Signaling Induces Enteric Glia Activation in Murine Postoperative Ileus (2019) (0)
Crystal structure of 1-propyl-8-(4-sulfophenyl)-7H-imidazo[4,5-d]pyrimidin- 2,6(1H,3H)-dione dihydrate, C14H14N4O5S 2H2O (1997) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Christa Elisabeth Müller?

Christa Elisabeth Müller is affiliated with the following schools:

University of Würzburg
University of Bonn

Christa Elisabeth Müller's Academic­Influence.com Rankings

Why Is Christa Elisabeth Müller Influential?

Christa Elisabeth Müller's Published Works

Published Works

What Schools Are Affiliated With Christa Elisabeth Müller?

Christa Elisabeth Müller's AcademicInfluence.com Rankings